Are we headed for a full-blown bear market? I honestly couldn’t tell you. But here’s what I can tell you: now is the time to give your portfolio a serious once-over. Not a gentle tidy-up. A full forensic accounting. Because let’s face it, hoping for the best is a strategy reserved for lottery tickets, not your future.
But hold on to your hats, because something…unusual…is happening. Besides the dividend – which, let’s be honest, was the only reason anyone was still holding onto this stock – Pfizer is suddenly…outperforming the S&P 500. Yes, you heard that right. It’s like the ugly duckling suddenly discovered it was secretly a swan…or at least a slightly less unattractive duck. The market, it seems, is starting to panic, and when the market panics, it buys dividend stocks. It’s a simple equation, really. Fear plus dividends equals…well, a temporary reprieve from financial ruin.
This venture falls, naturally, into the rather grandly-titled market of urban air mobility. Morgan Stanley, in a moment of optimistic forecasting, once suggested this market might reach a positively staggering $9 trillion by 2050. Should that prove to be the case, Joby, being one of the leading pioneers in this nascent field, might conceivably set today’s investors up for life. A thrilling prospect, wouldn’t you agree? Though, one must add, the Morgan Stanley estimate dates back to 2021, and the future, as any seasoned observer knows, has a habit of behaving in a most unpredictable fashion.
Artificial intelligence, that restless spirit of our time, is both architect and assailant. It presents a paradox: a tool to fortify our defenses, yet also the means to breach them with unprecedented subtlety. The old ways, the brute force of code and calculation, are giving way to a more fluid, insidious threat. It is no longer sufficient to be a craftsman of the digital world; one must anticipate the phantom hand, the echo of intelligence that learns and adapts with unsettling speed.
Transaction value based on SEC Form 4 weighted average purchase price ($62.12); post-transaction value based on March 18, 2026 market close. A precise accounting, of course, but one that feels…distant from the quiet anxieties of those who rely on such figures.
And they’ve been doing rather well for themselves, haven’t they? A positively stream of funds flowing in – CORP-DEPO Research tells me they had the lion’s share over the last quarter of last year. One suspects a great many people are simply tired of chasing rainbows and prefer a modicum of… predictability.
The figures, while substantial, require context. Mr. Cleveland retains a holding worth over $34 million, hardly suggesting a flight from the ship. Indeed, the sale represents a mere 8.9% of his direct holdings. One pictures a gentleman trimming his rose garden, not dismantling the entire estate.
The company had already benefited from a degree of encouragement, stemming from the recent revision of the National Comprehensive Cancer Network’s clinical guidelines. The inclusion of Anktiva®, in combination with Bacillus Calmette-Guérin, as a suitable treatment for certain bladder cancers unresponsive to simpler remedies, had provided a welcome boost. Now, it appears Macau’s authorities perceive a similar merit in this therapeutic alliance, granting approval for the very same patient cohort. One cannot help but observe that a favourable verdict, even in a smaller sphere, possesses a peculiar power to inspire confidence.
A lot of cybersecurity firms, it turns out, are still shipping around physical boxes. Great hulking machines filled with blinking lights and needing constant attention. It’s a bit like trying to run a modern hospital from a converted Victorian mansion. CrowdStrike, though, has embraced the cloud. Everything lives ‘up there’, which means no boxes, less electricity, and fewer frantic calls to IT when something goes wrong. This, they say, creates a ‘moat’ – a term economists seem particularly fond of. The idea is, it’s harder for competitors to dislodge you if you’ve built a really good, slippery moat. It’s a surprisingly effective metaphor, really. Though I do wonder if they’ve considered alligators.
One company currently caught in the delightful chaos is Viking Therapeutics (VKTX +2.23%). They haven’t quite managed to turn lead into gold, or, in this case, a consistently effective drug, but they’re heading in the right direction. And if they do succeed, well, let’s just say the shareholders might require larger carriages.